8-KEarnings & ResultsExhibits & Filings

ALNYLAM PHARMACEUTICALS, INC. 8-K Report, Financial Results (May 4, 2023)

Filed May 4, 2023For Securities:ALNY

Summary

Alnylam Pharmaceuticals, Inc. (ALNY) filed an 8-K on May 4, 2023, primarily to report its financial results for the quarter ended March 31, 2023. The key takeaway for investors is the release of these Q1 2023 financial and operational updates, which are detailed in the accompanying press release (Exhibit 99.1). This filing serves as the official channel for disseminating these important performance metrics. While the 8-K itself does not contain the detailed financial figures, it directs investors to the furnished press release for comprehensive information. Investors should review Exhibit 99.1 to understand Alnylam's revenue, earnings, and any significant operational developments or guidance changes announced during the period. It's important to note that the information provided in this 8-K, specifically Item 2.02, is furnished and not deemed "filed" for certain regulatory purposes, meaning it doesn't automatically become part of other SEC filings unless specifically incorporated.

Key Highlights

  • 1Alnylam Pharmaceuticals reported its financial results for the first quarter ended March 31, 2023.
  • 2The detailed Q1 2023 financial results and operational highlights are provided in a press release furnished as Exhibit 99.1.
  • 3Investors are directed to Exhibit 99.1 for comprehensive information regarding the company's performance.
  • 4The filing includes the standard Cover Page Interactive Data File.
  • 5Information furnished under Item 2.02 is not considered 'filed' for Section 18 of the Exchange Act or incorporated by reference unless specifically stated in other filings.

Frequently Asked Questions

The specific financial results for the quarter ended March 31, 2023, are detailed in the press release furnished as Exhibit 99.1 to this Form 8-K filing.

Information 'furnished' under Item 2.02 is provided to the SEC but is not subject to the same liability provisions as 'filed' information under Section 18 of the Exchange Act. It also won't be automatically incorporated into other SEC filings unless explicitly referenced.

Investors should look for key metrics such as revenue growth (especially from key products), net income or loss, earnings per share (EPS), cash flow, and any updates to financial guidance for the full year. Pipeline progress and clinical trial updates relevant to commercial performance may also be included.